ArticleScientific reports2025
Clinical and quality of life consequences of regimen switching delays in HIV management: a stratified cohort analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Health-related quality of life (HRQoL) in people living with HIV/AIDS (PLWHA) is shaped by a combination of HIV-related and non-HIV-related factors, including immunological and virological failure, HIV-associated comorbidities, and antiretroviral therapy (ART)-induced toxicity. Although HRQoL tends to improve during the first year of combination ART (cART), especially among those with advanced HIV, disparities persist. This cross-sectional analytical study assessed HRQoL in 321 PLWHA, of whom 310 were included in the final analysis. HRQoL was evaluated using the EQ-5D-5 L index. Of the participants, 121 (37.7%) had a high EQ-5D-5 L index value of 1, whereas 181 (58.9%) had an index value of less than 1. A statistically significant positive correlation was found between the EQ-5D-5 L index and the recent CD4-T cell count (rs = 0.162, p = .004). Gender-based analysis showed males (0.85 ± 0.15) had significantly higher HRQoL scores compared to females (0.77 ± 0.16). Furthermore, delayed switching to second-line regimens was associated with suboptimal recovery in HRQoL. These findings highlight the importance of timely clinical decisions in switching the ART to a more potent regimen especially in resource poor settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.